Savara Inc (SVRA):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Savara Inc (SVRA) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7100
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of treatment of PAP; and AeroVanc, an inhaled formulation of vancomycin for the treatment of CF. Its development pipeline also includes Aironite, a sodium nitrite solution for intermittent inhalation for the treatment of heart failure. The company has subsidiaries in the US and Denmark. Savara is headquartered in Austin, Texas, the US.

Savara Inc (SVRA) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Savara Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Savara Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Savara Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Savara Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Savara Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Savara Inc, Medical Equipment, Deal Details 10
Venture Financing 10
Savara Pharmaceuticals Secures USD18.54 Million in Venture Funding 10
Savara Pharma Raises US$14 Million In Series B Financing 11
Partnerships 12
Serendex Pharma Enters into Licensing Agreement with Pari Pharma 12
Equity Offering 13
Savara Prices Public Offering of Shares for USD48.9 Million 13
Savara Raises USD42.9 Million in Public Offering of Shares 14
Savara to Raise up to USD18 Million in Public Offering of Shares 15
Savara Raises USD8 Million in Public Offering of Shares and Warrants 16
Savara Raises USD21 Million in Public Offering of Shares and Warrants 17
Savara Raises USD0.9 Million in Public Offering of Shares up on Exercise of Warrants 18
Savara Raises USD30 Million in Public Offering of Shares 19
Savara Inc – Key Competitors 20
Savara Inc – Key Employees 21
Savara Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
May 09, 2018: Savara Reports First Quarter 2018 Financial Results and Provides Business Update 23
Mar 14, 2018: Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 25
Nov 08, 2017: Savara Reports Third Quarter 2017 Financial Results and Provides Business Update 27
Aug 09, 2017: Savara Reports Second Quarter 2017 Financial Results and Provides Business Update 28
Corporate Communications 29
Jan 04, 2018: Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Savara Inc, Medical Equipment, Key Facts, 2017 2
Savara Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Savara Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Savara Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Savara Inc, Deals By Market, 2012 to YTD 2018 8
Savara Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Savara Pharmaceuticals Secures USD18.54 Million in Venture Funding 10
Savara Pharma Raises US$14 Million In Series B Financing 11
Serendex Pharma Enters into Licensing Agreement with Pari Pharma 12
Savara Prices Public Offering of Shares for USD48.9 Million 13
Savara Raises USD42.9 Million in Public Offering of Shares 14
Savara to Raise up to USD18 Million in Public Offering of Shares 15
Savara Raises USD8 Million in Public Offering of Shares and Warrants 16
Savara Raises USD21 Million in Public Offering of Shares and Warrants 17
Savara Raises USD0.9 Million in Public Offering of Shares up on Exercise of Warrants 18
Savara Raises USD30 Million in Public Offering of Shares 19
Savara Inc, Key Competitors 20
Savara Inc, Key Employees 21
Savara Inc, Subsidiaries 22

List of Figures
Savara Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Savara Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Savara Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Savara Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Savara Inc (SVRA):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ICA Gruppen AB:企業のM&A・事業提携・投資動向
    ICA Gruppen AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ICA Gruppen AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Qiagen Marseille SA-製薬・医療分野:企業M&A・提携分析
    Summary Qiagen Marseille SA (HalioDx), formerly Ipsogen SA is a subsidiary of Qiagen NV, a drugs manufacturing company that develops and markets molecular diagnostic tests. The company offers products for the treatment of chronic myeloid, chronic lymphocytic, acute myeloid, and acute lymphoblastic l …
  • Torrent Power Limited:企業の戦略・SWOT・財務分析
    Torrent Power Limited - Strategy, SWOT and Corporate Finance Report Summary Torrent Power Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Bioverativ Inc (BIVV):医療機器:M&Aディール及び事業提携情報
    Summary Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technolog …
  • Lietuvos energijos gamyba, AB (LNR1L):電力:M&Aディール及び事業提携情報
    Summary Lietuvos energijos gamyba, AB (Lietuvos), a subsidiary of Lietuvos Energija UAB, is a state-controlled electric utility that generates, imports and exports, and supplies electricity and thermal energy. It generates electricity from hydro, thermal and renewable energy sources. The company tra …
  • Ossur hf (OSSR):企業の財務・戦略的SWOT分析
    Ossur hf (OSSR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Sebia SA:医療機器:M&Aディール及び事業提携情報
    Summary Sebia SA (Sebia) is a medical device company that designs, manufactures, commercializes, and exports electrophoresis tests and analyzers. The company's electrophoresis program offers automated system for capillary electrophoresis, gel electrophoresis and electrophoresis scanning software. It …
  • BioRestorative Therapies Inc (BRTX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioRestorative Therapies Inc (BRT), formerly Stem Cell Assurance Inc is a developer of therapeutic products and medical therapies. The company performs stem cell programs which include brtxDISC and ThermoStem. brtxDISC,a lead therapeutic product, is designed to offer a non-surgical treatment …
  • Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報
    Summary Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise aging and regenerative medicine, cancer biology, immune system biology, metabolism and diabetes, neuroscience and neurological disorders, …
  • SCIO Health Analytics:企業の戦略的SWOT分析
    SCIO Health Analytics - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Luna Innovations Inc (LUNA):企業の財務・戦略的SWOT分析
    Summary Luna Innovations Inc (Luna) is an optical technology development company that research, develops and commercializes speed optics and fiber optic test products. The company provides products such as fiber optic sensing products, fiber optic test and measurement products, high speed optical pr …
  • DHL Parcel UK Ltd:企業の戦略的SWOT分析
    DHL Parcel UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Lombard Odier Private Clients:企業の戦略・SWOT・財務情報
    Lombard Odier Private Clients - Strategy, SWOT and Corporate Finance Report Summary Lombard Odier Private Clients - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Cara Therapeutics Inc (CARA):製薬・医療:M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • PetroChina Co Ltd (857):企業の財務・戦略的SWOT分析
    PetroChina Co Ltd (857) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Achelios Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Achelios Therapeutics Inc (Achelios) is a pharmaceutical company that develops therapeutics for the treatment of pain and inflammation by topically delivered medications. The company’s lead products include Topofen, a product for the indication of acute migraine, prophylactic migraine, osteo …
  • Zincore Metals Inc:企業の戦略・SWOT・財務分析
    Zincore Metals Inc - Strategy, SWOT and Corporate Finance Report Summary Zincore Metals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Amazon Web Services Inc:企業の戦略・SWOT・財務分析
    Amazon Web Services Inc - Strategy, SWOT and Corporate Finance Report Summary Amazon Web Services Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • S-Oil Corporation Inc (010950)-石油・ガス分野:企業M&A・提携分析
    Summary S-Oil Corporation Inc (S-Oil) is a service driven company that operates in the petroleum and petrochemical industry. The company imports and exports crude oil; as well as manufactures and sells oil refining products, petrochemical products and lube products. S-Oil also produces a wide range …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆